Sonelokimab Development For HS Continues With Phase 3 Trial Initiation As I stated above, since the last update I did on MoonLake, it has been able to make substantial progress in advancing the use of its drug sonelokimab for the treatment of patients with moderate-to-severe hidradenitis suppurativa [HS]. Matter of fact, it obtained positive feedback from both the FDA and the European Medicines Agency [EMA] to develop this drug in late-stage clinical testing. That is, it had been able to initiate the phase ...